tbuckley/cabot-search huggingface dataset:
PTH-080 Serious Infusion Reactions with Vedolizumab are Rare: A UK Multicenter Experience
Authors: P Irving, C Lees, A Hart, K Kemp, T Ahmad, F Cummings
Journal: Gut (2016)

<h3>Introduction</h3> Vedolizumab has recently become widely available in the UK for the treatment of moderate to severe ulcerative colitis (UC) and Crohn’s disease (CD). This has created pressure on infusion services exacerbated by the improved access to infliximab for UC and the ever increasing number of patients with CD receiving IFX. The UK Summary of Product Characteristics, unlike in the US, mandates post-infusion monitoring of patients for 2 hours after the first 2 infusions and for 1 hour after subsequent infusions. We have, therefore, reviewed the frequency of infusion reactions during and after infusions of vedolizumab in 6 UK IBD centres. <h3>Methods</h3> Details of the numbers of vials of vedolizumab supplied to each centre were provided by Takeda UK. All centres identified patients on vedolizumab who had had possible infusion-related reactions and reported the details after review of the case record. <h3>Results</h3> Across the 6 centres, 1132 vials of vedolizumab had been supplied for infusion up until 5<sup>th</sup> March 2016. 9 possible infusion reactions were identified involving 9 patients. 1 reaction occurred during the infusion, 1 in the 2 hours after the infusion and 7 more than 2 hours after the infusion. One anaphylactoid reaction occurred on the second infusion in a patient with Crohn’s disease on concomitant mercaptopurine. The infusion was stopped and no further infusions of vedolizumab were given. Other possible infusion-related reactions included headache (2), rash (3), nausea and blurred vision (1), vasovagal symptoms (1), and palpitations (1). Only one reaction occurred in the 2 hours following the infusion. This was a patient who experienced palpitations who had consumed several cups of coffee whilst waiting to be discharged. Other than the patient with an anaphylactoid reaction, none of the other reactions led to discontinuation of vedolizumab. <h3>Conclusion</h3> Vedolizumab infusion reactions are rare. Only one anaphylactoid reaction was seen in over 1000 infusions. No definite reactions occurred in the 2 hours after infusions suggesting that monitoring patients for 2 hours after the first 2 infusions and for 1 hour after subsequent infusions is probably unnecessary. Overall, the frequency of infusion reactions is low as was seen in the Gemini studies. <h3>Disclosure of Interest</h3> P. Irving Grant/research support from: AbbVie, MSD, Consultant for: AbbVie, MSD, Vifor, Genentech Inc., Takeda, Warner Chilcott, Falk and Pharmacosmos, Speaker bureau with: AbbVie, MSD, Ferring, Warner Chilcott, Shire, Falk and Johnson and Johnson, C. Lees: None Declared, A. Hart: None Declared, K. Kemp: None Declared, T. Ahmad: None Declared, F. Cummings: None Declared
THE PROTEOMIC CLASSIFIER VERISTRAT (R) IDENTIFIES ADVANCED NON SMALL CELL LUNG CANCER (NSCLC) PATIENTS GAINING CLINICAL BENEFIT FROM TREATMENT WITH FIRST LINE SORAFENIB AND ERLOTINIB
Authors: Egbert F. Smit, Heinrich Roder, Julia Grigorieva, J. Roder, Joline S. W. Lind, Anne-Marie Dingemans, Harry J. M. Groen
Journal: Journal of Thoracic Oncology (2011)
P1333 : A randomized, double-blind study of the effects of omega-3 fatty acids (Omegaven™) on outcome after major liver resection
Authors: M. Linecker, P. Limani, F. Botea, I. Popescu, R. Alikhanov, M. Efanov, I. Khatkov, D. Raptis, C. Tschuor, B. Beck Schimmer, J. Bonvini, A. Wirsching, P. Kron, K. Slankamenac, B. Humar, R. Graf, H. Petrowsky, P.A. Clavien
Journal: Journal of Hepatology (2015)
Circularly Permuted TRAIL (CPT) combined with Thalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma: An Open-Label, Multicenter Phase II Clinical Trial.
Authors: Wenming Chen, Jian Hou, Yaozhong Zhao, Lugui Qiu, Xiaoyan Ke, Zhao Wang, Yun Leng, Hongmei Jing, Hao Xi, Xiangjun Zheng, Fuxu Wang, Bing Zhu, Shifang Yang
Journal: Blood (2012)
The Physician-Patient Relationship Impacts Patient Quality of Life in Chronic Lymphocytic Leukemia: Results of an International Survey of 1482 Patients.
Authors: Tait D. Shanafelt, Deborah Bowen, Chaya Venkat, Susan L. Slager, Clive S. Zent, Neil E. Kay, Megan Reinalda, Jeff A. Sloan, Timothy G. Call
Journal: Blood (2007)
Therapy-activated stromal cells can dictate tumor fate
Authors: Robert S. Kerbel, Yuval Shaked
Journal: The Journal of Experimental Medicine (2016)

In this issue of JEM, Chan et al. describe a novel way by which an investigational form of chemotherapy known as low-dose metronomic chemotherapy can inhibit tumor growth, which also has therapeutic implications for targeting tumor-initiating cells (TICs), the tumor stroma, and chemokine receptors, as well as invasion and metastasis.
Endoscopic submucosal dissection of pancreatic heterotopia in children
Authors: Yvonne Leung, Christoph Houben, Mabel Lacambra, Anthony Teoh, Yuk Tam, Philip Chiu
Journal: Endoscopy (2016)

Aberrant pancreatic tissue is mostly found in the submucosal layer of the upper gastrointestinal tract, occurring in 1.7 % of the population according to summarized post-mortem studies [1]. Gastric pancreatic heterotopia was first recognized by Klob in 1859 [2].
Effect of Age and Weight on Toxicity and Survival in Pediatric Acute Myeloid Leukemia
Authors: Ditte Juel Adolfsen Løhmann, Jonas Abrahamson, Shau Yin Ha, Ólafur G. Jónsson, Minna Koskenvuo, Birgitte Lausen, Josefine Palle, Bernward Zeller, Henrik Hasle
Journal: Blood (2015)
AB0338 Survival of Biological Drugs in The Treatment of Chronic Inflammatory Arthropathies
Authors: A. Martin Vila, R. Melero Gonzalez, N. MartÍnez Lόpez de Castro, M. Άlvarez Payero, M.R. Rodriguez, F. Maceiras Pan, C. Mouriño, M. Rodríguez Lόpez, I. Hernández Rodriguez, C. Barbazán Άlvarez, M. Samartin Ucha, V. Balboa Barreiro, J. De Uña Άlvarez, G. Piñeiro Corrales, J.M. Pego Reigosa
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> To analyze the survival of treatment lines with different biologics in a cohort of patients diagnosed with rheumatoid arthritis (RA), psoriatic arthritis (AP), ankylosing spondylitis (AS) and other spondyloarthropathies (O). <h3>Methods</h3> Retrospective observational study.All patients who had been treated with a biological drug for at least six months during the period between 01/01/2009 and 31/08/2014, for any of the previously specified indications were included.In addition to demographic data, all lines of treatment received from the diagnosis and the duration of them were collected.It has been analyzed whether there were differences in the duration of treatment depending upon the drug and the disease. A survival analysis of all lines of treatment was performed using the Kaplan-Meier curves for each drug, including those who had not finished.It was represented on the vertical axis the percentage of patients who had each treatment and in the other axis, duration in days.It was analyzed whether there were differences between these curves using the log-rank test. <h3>Results</h3> We studied 484 patients with a mean age of 56 years (SD 14.4), 54.3% women. 742 lines of treatment were analyzed. Drug distribution: Adalimumab 344, etanercept 219, infliximab 96, golimumab 20, certolizumab 6, abatacept 20 and tocilizumab 26. In the cutoff point of the study (31.AUG.2014) had completed 342 of these lines. The average duration of treatment in days (± SD) was calculated with the following results: Adalimumab: 1034 (±864)days; Etanercept: 735 (±768)days; Infliximab: 959 (±845) days; Golimumab: 302 (±225)days; Certolizumab: 90±0 days; Abatacept: 429 (±360)days; Tocilizumab: 328 (±337)days. The average length of treatment depending on the pathology (± SD) was also calculated. AR: 989 (±853)days; AP: 975 (±843)days; EA: 766 (± 677)days and O: 912 (±920)days.Given the standard deviations found, a survival analysis was performed using the Kaplan-Meier curves.Significant difference were observed when comparing the drugs 2–2 for the following pairs:adalimumab and infliximab have longer lines comparing to golimumab, certolizumab, abatacept and tocilizumab (p&lt;0.05) and etanercept longer than golimumab, certolizumab and tocilizumab (p&lt;0.01). <h3>Conclusions</h3> The duration of treatment lines is variable in all drugs and for all conditions tested. No differences were found with regard to the length of the lines between the three drugs analyzed with a longer time since its commercialization: adalimumab, etanercept and infliximab. Supported by an unrestricted grant from Pfizer. <h3>Disclosure of Interest</h3> None declared
SAT0059 Criteria for Choice by Clincians of The Therapeutic Strategy in Patients with Insufficient Response To A First Anti-TNF: Data from The Randomized “Roc” Criteria
Authors: E. Chatelus, C. Sordet, P. Ravaud, J. Sibilia, J.-E. Gottenberg
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Therapeutic strategy after failure of a 1st anti-TNF (TNF-IR) is not codified in rheumatoid arthritis (RA). Little is known about the criteria for choice of a second biologic by clinicians. <h3>Objectives</h3> To determine whether patient9s or disease characteristics guide clinicians for their choice of a second biologic in TNF-IR patients with RA <h3>Methods</h3> The ROC trial randomized patients with an insufficient response to a 1st anti-TNF to receive either a second anti-TNF or a non-TNF targeted biologic. Before randomization, the clinician9s preference for the second biologic (either a non-TNF targeted biologic or a second anti-TNF) was collected. After randomization, the choice of the molecule within each arm was left to the clinician. <h3>Results</h3> The clinician9s preference for the second biologic could be collected before randomization for 281 out of the 292 patients analyzed in the ROC trial. 151 clinicians would have preferred to prescribe a non-TNF targeted biologic, 72 a second anti-TNF and 58 clinicians had no preference. Among baseline characterics of disease, only disease duration was significantly associated with the preference for non-TNF targeted biologics (median 8 [3–17] years for patients for whom clinicians would have chosen a non-TNF biologic versus 5 [1–13] years for patients for whom clinicians would have chosen a second anti-TNF, p=0.001). Other parameters (such as age, sex, body mass index, number of previous conventional DMARDs, seropositivity for RF/ACPA, extra-articular invovement, CRP, ESR, DAS28-ESR at inclusion) has no significant impact on the clinician9s choice.Cotreatment either with glucocorticoids, methotrexate or anopther conventional DMARD had no significant impact on the choice of clinicians either. With regards to the choice of the mechanism of action in the non-TNF targeted group, clinicians significantly more frequently prescribed abatacept in patients with cardiovascular risk factors (70% of patients treated with abatacept had cardiovascular risk factors compared to 44% of patients treated with rituximab or tocilizumab) p=0.03). Clinicians prescribed significantly more frequently tocilizumab in patients with a high C-reactive protein value (median baseline value of 10.5 mg/l versus 5 mg/l in patients who received abatacept or rituximab) (p=0.01). <h3>Conclusions</h3> There is no characteristic patient9s profile explaining the preference of clincians for a non-TNF biologic or a second anti-TNF in TNF-IR patients. Among non-TNF biologics, abatacept was more frequently prescribed in patients with cardiovascular risk factors and tocilizumab was more frequently prescribed in patients with a high C-reactive protein value. <h3>Disclosure of Interest</h3> None declared
P0808 : Improvement in liver function and non-invasive estimates of liver fibrosis 48 weeks after treatment with ombitasvir/paritaprevir/R, dasabuvir and ribavirin in HCV genotype 1 patients with cirrhosis
Authors: H. Wedemeyer, T. Berg, S.L. Flamm, G.R. Foster, A. Craxi, D. Larrey, T.R. Morgan, M.W. Fried, F. Poordad, R. Trinh, S. Lovell, Y. Tang, M. Pedrosa, J.-C. Lopez-Talavera, I.M. Jacobson
Journal: Journal of Hepatology (2015)
Outcomes Of Allogeneic Hematopoietic Stem Cell Transplantation In AML Patients Registered In Prospective Studies: The JALSG Experience
Authors: Ken Ishiyama, Shigeki Ohtake, Hisashi Sakamaki, Yasushi Miyazaki, Shuichi Miyawaki, Kazunori Ohnishi, Tomoki Naoe
Journal: Blood (2013)
Epigenetic Regulation of Cancer-Testis Antigen Expression in Multiple Myeloma and Correlation with High-Risk Cytogenetics.
Authors: Zandra K. Klippel, Akshay Srivatsan, Andrea M. H. Towlerton, Jeffrey Chou, Tuna Mutis, Henk Lokhorst, William I. Bensinger, Edus H. Warren
Journal: Blood (2012)
Clinical Phenotype and Long Term Outcome in a Large Cohort of X-Linked Thrombocytopenia (XLT)/Mild Wiskott-Aldrich-Syndrome Patients
Authors: Michael H Albert, Tanja Bittner, Daniel Stachel, Shigeaki Nonoyama, Lucia Notarangelo, Siobhan Burns, Isabelle Pellier, Gabriele Strauss, Tomohiro Morio, Kohsuke Imai, Teresa Espanol, Benjamin Gathmann, Manfred Hönig, Jeroen G Noordzij, Michaela Nathrath, Alfons Meindl, Uwe Wintergerst, Alain Fischer, Adrian Thrasher, Bernd H Belohradsky, Hans D Ochs
Journal: Blood (2008)
Outbreak of shiga toxin-producing Escherichia coli O157 infection associated with a day camp petting zoo - Pinellas County, Florida, May-June 2007.
Authors: K. A. Alelis, P. E. Borkowski, P. Fiorella, J. Nasir, J. Middaugh, C. Blackmore, J. Keen
Journal: MMWR Morbidity and Mortality Weekly Report (2009)
Dose Adjusted IV Busulfan/Cyclophosphamide (BU/CY) and Autologous (AU) Stem Cell Transplantation (SCT) for Recurrent Lymphoma.
Authors: Thomas R. Spitzer, Benjamin Cox, Paul Sepe, Steven L. McAfee, Bimalangshu R. Dey, Karen Ballan, David Scadden
Journal: Blood (2004)
In Imatinib Treated CML Patients with Low Baseline IC50, Early Molecular Response Is Highly Predictive of Longer Term Molecular Outcome. In Patients with High IC50, Other Prognostic Indicators Are Needed.
Authors: Deborah L. White, Susan Branford, Verity A. Saunders, Kevin Lynch, Andrew Grigg, L. Bik To, Timothy P. Hughes
Journal: Blood (2005)
Enhanced HDAC (Histone Deacetylase) Enzyme Activities in Blood CD 34 + Cells in Patients with Myeloid Metaplasia Myelofibrosis (MMM).
Authors: Jen-Chin Wang, Chi Chen, Theresa Dumlao, Thong Chang, Yng-Li Xiao, Inna Sominsky, Jack Burton
Journal: Blood (2007)
Promise of new Alzheimer’s drug is dashed after lack of evidence
Authors: Nigel Hawkes
Journal: BMJ (2016)

The hope that a failed Alzheimer drug, solanezumab, might prove effective in patients with mild disease has proved misplaced after a phase III trial in this group of patients produced no significant benefits.

The trial was the last throw of the dice for Eli Lilly in its pursuit of a blockbuster drug for Alzheimer’s disease. Solanezumab, a monoclonal antibody targeting amyloid plaques, the pathological signature of the disease, had failed an earlier phase III trial in 2012. But close examination of the results suggested that while it did not reverse the disease, it may have slowed its progress.1

People given the drug earlier declined at a similar rate to those given it later, but a gap persisted between the …
PTU-105 Cytoreductive Surgery and Small Bowel Transplantation is A Feasible Option for Patients with End-Stage Pseudomyxoma Peritonei
Authors: P Allan, S Reddy, B Moran, G Vrakas, H Giele, F Mohamad, J Gilbert, S Sinha, A Vaidya, T Cecil, P Friend
Journal: Gut (2016)

<h3>Introduction</h3> Pseudomyxoma peritoneii (PMP) arising from a low grade appendix tumour has good outcomes from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. In those that recur or present with extensive small bowel involvement preventing complete tumour removal, obstruction leads to poor quality of life and is eventually fatal. Small bowel transplant could offer a life prolonging opportunity in endstage disease. <h3>Methods</h3> From 2013–2015, 4 PMP patients were referred for consideration of small bowel transplantation with end stage disease and intestinal failure. Outcomes include time on PN, mortality, rejection, nutritional status, tumour markers, radiological evidence of recurrence and quality of life. <h3>Results</h3> All 4 patients underwent radical debulking and small bowel transplantation. Average time on waiting list was 40 days (range 2–112). Organs transplanted: all were modified multivisceral transplants including stomach, duodenum-pancreatic complex, small bowel and abdominal wall; 3 received colon and 1 case a kidney. Median cold ischaemia time was 6hrs 59 mins (range 5hr 46 to 10 hr 22, 3 cases). Post-op stay on ITU average 14.5 days (range 2–45). Time on PN postoperatively: median 31 (range 19–51). Mortality risk: 2 survived at time of review, 11 months and 7 months; 2 died (Day 26 and day 64) the first from anastomotic leak, GVHD with associated fungal and bacterial chest sepsis, the other died of GI bleed and anastomotic leak. No episodes of acute rejection of intestinal graft seen but a single episode of grade 1 skin rejection of abdominal wall graft at day 68 treated with methylprednisolone. QOL data using EQ5D: pre-transplant 3 patients gave a VAS average 30 (range 10–75). Post-transplant VAS median 75 (70–80) at 2–4 months. Both the surviving patients are independent of TPN and well at home. <h3>Conclusion</h3> From this preliminary series, cytoreductive surgery followed by multi-visceral small bowel transplantation is technically feasible for endstage PMP. Furthermore, in those who survived, it is has been life transforming giving so far an extra 7–11 months independent of TPN and excellent QOL. The long term outcomes will determine the effectiveness of this procedure. Early referral might allow surgery in physiologically fit patients improving the outcomes. This major surgical intervention requires close collaboration between Peritoneal Malignancy &amp; Transplant teams. <h3>Disclosure of Interest</h3> None Declared
Generation of a Novel Bispecific Antibody (ACE910) Against Activated Factor IX and Factor X Mimicking the Function of Factor VIII Cofactor Activity
Authors: Tomoyuki Igawa, Zenjiro Sampei, Tetsuhiro Soeda, Yukiko Okuyama-Nishida, Chifumi Moriyama, Tetsuya Wakabayashi, Eriko Tanaka, Atsushi Muto, Tetsuo Kojima, Takehisa Kitazawa, Kazutaka Yoshihashi, Aya Harada, Miho Funaki, Kenta Haraya, Tachibana Tatsuhiko, Sachiyo Suzuki, Keiko Esaki, Yoshiaki Nabuchi, Kunihiro Hattori
Journal: Blood (2012)
Renal replacement therapy for refugees with end-stage kidney disease: an international survey of the nephrological community
Authors: Wim Van Biesen, Raymond Vanholder, Bert Vanderhaegen, Norbert Lameire, Christoph Wanner, Andrzej Wiecek, Mehmet S. Sever, Johan Feehally, Remuyza Kazancioglu, Eric Rondeau, Adeera Levin, David Harris
Journal: Kidney International Supplements (2016)
SAT0287 Ethnic Differences Strongly Influence The Phenotypic Expression of Primary Sjögren: Study of 7887 Patients from 20 Countries on 5 Continents (EULAR-SS Task Force Big Data Sjögren Project)
Authors: P. Brito-Zerόn, N. Acar-Denizli, M. Zeher, A. Rasmussen, R. Seror, T. Mandl, X. Li, C. Baldini, J.-E. Gottenberg, D. Danda, L. Quartuccio, R. Priori, G. Hernández-Molina, A. Kruize, V. Valim, M. Kvarnstrom, D. Sene, R. Gerli, S. Praprotnik, D. Isenberg, R. Solans, M. Rischmueller, S.-H. Park, G. Nordmark, Y. Suzuki, R. Giacomelli, A. Saraux, M. Bombardieri, B. Hofauer, H. Bootsma, D. Hammenfors, G. Fraile, S. Carsons, T. Gheita, J. Morel, C. Vollenveider, F. Atzeni, S. Retamozo, I.-F. Horvath, K. Sivils, E. Theander, P. Sandhya, S. De Vita, J. Sanchez-Guerrero, E. van der Heijden, V. Moça-Trevisano, M. Wahren-Herlenius, X. Mariette, M. Ramos-Casals
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> To analyse the influence of ethnicity on the clinical presentation at diagnosis in an international cohort of patients with primary Sjögren syndrome (pSS). <h3>Methods</h3> The Big Data Sjögren Project is a multicentre registry formed by international experts from the EULAR-SS Task Force. By January 2016, the database included 8315 consecutive patients fulfilling the 2002 AE criteria (20 countries, 5 continents). Ethnicity was classified according to FDA (White=W, Black/African American=B, Asian=A, Hispanic=H, Others=O). <h3>Results</h3> Ethnicity data was available in 7887 (95%) patients: 6177 W (78%), 1066 A (13%), 393 H (5%), 104 B (1%) and 147 O (2%). European patients were overwhelmingly white compared with Americans (96% vs 52%, p&lt;0.001). The greatest differences between ethnicities (p&lt;0.001) were observed for mean age at diagnosis (47yrs in B vs 54yrs in W), and the frequency of males (12% in B vs 4% in A), dry eyes (76% in A vs 98% in O), dry mouth (83% in A vs 99% in O), abnormal ocular tests (79% in O vs 90% in H), abnormal oral tests (65% in O vs 91% in H), positive minor salivary biopsy (75% in O vs 95% in H), positive anti-Ro (54% in O vs 84% in A) and positive anti-La (28% in O vs 50% in A). <h3>Conclusions</h3> White patients had the oldest age at diagnosis, Black/African Americans the highest frequency of men and the lowest mean age, Asians the highest frequency of women, the lowest frequency of sicca symptoms and the highest frequency of Ro/La and Hispanics the highest frequency of abnormal diagnostic tests. Ethnicity plays a capital role in the phenotypic expression at diagnosis of primary SS. <h3>Disclosure of Interest</h3> None declared
Germinal Center Generation and Maintenance By T Follicular Helper Cells Is Required For The Development Of Chronic Gvhd Associated Bronchiolitis Obliterans In a Preclinical Model
Authors: Ryan Flynn, Jing Du, Rachelle Veenstra, Angela Panoskaltsis-Mortari, Andrew Price, Patricia A Taylor, Gordon J Freeman, Jeffrey L Browning, Jonathan Serody, William J Murphy, David Munn, Stefanie Sarantopoulos, Leo Luznik, Ivan Maillard, John Koreth, Corey S. Cutler, Robert J Soiffer, Joseph H. Antin, Jerome Ritz, Jason A Dubovsky, John C. Byrd, Kelli MacDonald, Geoffrey R Hill, Bruce R Blazar
Journal: Blood (2013)
Notch Signaling-Dependant Expulsion of Parasites through Mast Cell-Mediated Immunity.
Authors: Mamiko Sakata-Yanagimoto, Etsuko Yamaguchi-Nakagami, Toru Sakai, Keiki Kumano, Atsushi Kunisato, Aleksandra Crcareva, Mineo Kurokawa, Seishi Ogawa, Koji Yasutomo, Hisamaru Hirai, Shigeru Chiba
Journal: Blood (2004)
The Efficacy of Vemurafenib in Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Preliminary Results from VE-Basket Study
Authors: David M. Hyman, Eli Diamond, Vivek Subbiah, Jean-Yves Blay, A. Craig Lockhart, Omar Abdel-Wahab, Florin Sirzen, Maria Luisa Veronese, Susan Frances Laserre, Elena Elez, Jose Baselga
Journal: Blood (2014)
Somatic Structural Variations in Pediatric High Hyperdiploid Acute Lymphoblastic Leukemia Revealed by Paired-End Parallel Sequencing
Authors: Cai Chen, Christoph Bartenhagen, Michael Gombert, Vera Okpanyi, Vera Binder, Silja Roettgers, Jutta Bradtke, Andrea Teigler-Schlegel, Ute Fischer, Jochen Harbott, Jianda Hu, Martin Dugas, Arndt Borkhardt
Journal: Blood (2011)
Genetic Polymorphism of the Complement Receptor-1 (CR1) Gene Correlates with the Clinical Response to Eculizumab of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Authors: Tommaso Rondelli, Antonio M. Risitano, Régis Peffault de Latour, Benedetta Peruzzi, Ricci Patrizia, Wilma Barcellini, Anna Paola Iori, Carla Boschetti, Veronica Valle, Veronique Frémeaux-Bacchi, Maria De Angioletti, Gerard Socie, Lucio Luzzatto, Rosario Notaro
Journal: Blood (2012)
Outcome of Allogeneic Stem Cell Transplantation for Patients with Severe Aplastic Anemia after Conditioning with Procarbazine, ATG and Cyclophosphamide: A Single Center Experience.
Authors: Ki Seong, Jong Wook Lee, Yoo Jin Kim, Hee Je Kim, Chang Ki, Seok Lee, Sung Yong, Woo Sung, Chun Choo Kim
Journal: Blood (2005)